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The Incidence of Atorvastatin-induced Abnormal Liver Function in Chinese
Patients: A Systematic Review and Meta-analysis
Jianping Li,1 Shixian Chen,2 Na Qin,2 Mengxi Chen,2 Shaowen Tang2
1Department of Cardiology, Peking University First Hospital;
2Department of Epidemiology, Nanjing Medical University
OBJECTIVES To study the incidence of atorvastatin-induced
abnormal liver function in Chinese patients.
METHODS Literatures were searched in PubMed, EMBASE, CENTRAL,
SinoMed, CMCI, CNKI, VIP and Wanfang database (from their incep-
tion to Feb 8, 2015). Randomized controlled trial (RCT), Cohort Study,
case series and quasi-experiment studies were included, and generic
drugs were excluded. Data extraction and veriﬁcation were conducted
by two reviewers independently. Open Meta-Analyst software with
binary random effect model was applied to compute the incidence of
atorvastatin-induced abnormal liver function in different doses and
periods, and the results were described by rates and 95% conﬁdence
intervals (95% CI).
RESULTS According to our searching strategy and including criteria,
2386 literatures (2298 Chinese literatures and 88 English ones)
published between 2001 and 2015 were included, among which there
were 1984 RCT studies, 45 cohort studies, 258 case series studies and
99 quasi-experiment studies. 1140 literatures reported the adverse
drug reactions (ADRs) in the process of follow-up, but 1246 litera-
tures did not explicitly mentioned any ADRs. 182430 patients with
different diseases such as coronary heart disease, acute coronary
syndromes, unstable angina pectoris, hyperlipidemia, atherosclerosis
were analyzed. The maximum treatment time was 7 years. Based on
the studies reported ADRs (1140 literatures), the numbers of patients
in 10mg/d, 20mg/d, 40mg/d and 80mg/d groups were 29079, 54020,
9255 and 1216, respectively, and the corresponding incidence and
95%CI of atorvastatin-induced abnormal liver function were 1.1%
(0.9%w1.2%), 1.2% (1.1%w1.3%), 1.3% (1.1%w1.5%) and 2.7% (1.4%w
3.9%), respectively. There were no signiﬁcant differences among
different treatment periods in the same dose group. Based on all
2386 literatures, the numbers of patients were 52030, 106009, 18840
and 3352 in four groups, respectively, and corresponding incidence
of atorvastatin-induced abnormal liver function were 0.6% (0.5%w
0.7%), 0.03% (0.02%w0.05%), 0.6% (0.5%w0.7%) and 0.9% (0.6%w
1.2%) with the assume that those studies not mentioned ADRs were
the ones with no ADRs. When based on hepatic transaminases > 3
times the upper limit of normal in literatures reported ADRs, the
incidence and 95%CI of atorvastatin-induced hepatitis were 0.9%
(0.6%w1.1%), 0.9% (0.7%w1.1%), 1.0% (0.6%w1.3%) and 1.4%
(0.2%w2.5%) in 10mg/d, 20mg/d, 40mg/d and 80mg/d groups,
respectively. In addition, there were 6, 1, 10 and 17 literatures
described 5mg/d, 15mg/d, 30mg/d and 60mg/d, respectively, and
with few cases of abnormal liver function in each groups (2/566,
1/64, 11/592 and 14/977, respectively).
CONCLUSIONS The incidence of atorvastatin-induced abnormal liver
function in Chinese patients were very low.
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Effect of phosphocreatine on angiotensininIIinduced proliferation and
collagen synthesis in neonatal rat cardiac ﬁbroblasts
Zihan Wei, Ying Wang
the First Afﬁliated Hospital, Zhengzhou University
OBJECTIVES The aim of this study is to investigate the effect of
phosphocreatine (PCr) on angiotensinII(AngII)–induced cardiac
ﬁbroblasts in neonatal rats in vitro and to clarify its mechanismof
action.
METHODS The model of myocardial ﬁbrosis induced by AngIIwas
established, the effect of phosphocreatine on cultured cardiac ﬁbro-
blasts(CF) proliferation in the presence or absence of excessive
angiotensinII(AngII) was assessed by ﬂow cytometric assay, the area
of myocardial collagen was observed by VG staining and the expres-
sion of the phosphorylated extracellular signal-regulated kinase
(pERK1/2) was detected by immunohistochemistry in each group. The
cardiac ﬁbroblasts were randomly divided into four groups: ① the
control group② the AngII group (110-6mol/L)③ the phosphocreatine
treated group (10mmol/L) ④ the AngII þphosphocreatine treated
group (110-6mol/L þ10mmol/L).
RESULTS The model of myocardial ﬁbrosis was successfully estab-
lished. Compared to the control group, distribution of CFs in G0/G1
and G2/M phase in AngIIgroup was decreased (P<0.01) with
conversely, the increase of the proporation in S phase, the collagensynthesis and the expression of pERK1/2 protein of CFs(P<0.01).
However, no signiﬁcant difference was observed in cell cycle distri-
bution, collagen synthesis of CFs and the expression of pERK1/2
protein between the control and the phosphocreatine treated
group(P>0.05). Compared to the AngIIgroup, the percentage of CFs in
the G0/G1 phase and G2/M phase was increased with simultaneously,
the reduction of S phase and the collagen synthesis in AngIIþphos-
phocreatine treated group (P<0.01). Noteworthy, phospho-status of
ERK1/2 in the AngIIþphosphocreatine treated group demonstrated a
higher expression than that in the control group as well as lower than
in the AngIIgroup (P<0.01).
CONCLUSIONS Our study shows that phosphocreatine plays a crucial
role in the inhibition of myocardial ﬁbrosis induced by AngIIthrough
partially suppressing the CF proliferation and collagen synthesis,
which is possibly associated with the inhibition of excessively acti-
vated ERK1/2.GW26-e1296
A research on initial dosage of warfarin and target ratio
Guo Huijun, Xiuchun Yang, Jingchao Lu, Fan Liu
Second Hospital of Hebei Medical University
OBJECTIVES To further acknowledge the optimal initial dosage and
offer more reasonable evidence for the application of warfarin in
clinical work, the research is adopted by comparing the efﬁcacy
and safety of the two dosage regimens to the patients with atrial
ﬁbrillation (AF) or pulmonary embolism (PE) by using different
initial dosages of warfarin according to the warfarin 3mg and to the
BMI.
METHODS 81 patients using oral warfarin were randomly assigned to
two groups according to different kinds of dosage regimen. The con-
trol group included 42 cases started with 3 mg while research group
included 39 cases, started with the initial warfarin dosage by the guide
of body mass index (BMI) (BMI<25,3mg;25BMI<30,4.5mg;
BMI30,6mg). Follow up one month, to compare the time that INR
ﬁrst stabilized at target range(2.0w3.0), the ratio within stabilized
target range at different time, the time that INR stabilized at target
range, the times to exceed therapeutic INR (INR>3.0), maintenance
dose, and the incidence of bleeding or thrombosis episodes.
RESULTS There was no statistical signiﬁcance between the two
groups in baseline characteristics included age, sex, height, weight,
BMI, comorbid conditions, drug combination, Baseline INR, left atrial
thrombus and pulmonary embolism. Comparing the safety between
two groups: there were two cases bleeding slightly in control group
and one case in research group, Both groups had no thrombotic
events, There was no statistical signiﬁcance between the two groups
(P¼1.0). There were no statistical signiﬁcance between the two groups
in the incidence rate to exceed therapeutic INR in different time
(P>0.05).There was 7 cases in control group to exceed therapeutic INR
at day 15, and 13 cases in research group, There was no statistical
signiﬁcance between the two groups (P¼0.082, P>0.05). Comparing
the effectiveness between two groups: compared with control group,
the ratio to achieve therapeutic INR at day 3, day 5, day 7 were
signiﬁcantly higher in research group ( 38.9% vs. 11.9% at day 3, 51.3%
vs. 23.8% at day 5, 71.8% vs. 45.2% at day 7), There was statistical
signiﬁcance between the two groups (P<0.05). Compared with control
group, research group required a signiﬁcantly shorter time to achieve
therapeutic INR at the ﬁrst time (5 days vs. 7 days), There was sta-
tistical signiﬁcance between the two groups (P<0.05). There was no
statistical signiﬁcance between the two groups in the time that INR
stabilized therapeutic INR (12 days in research group vs. 15 days in
control group), but compared with control group, research group was
faster. There was statistical signiﬁcance between the two groups
(P<0.05) in maintenance dose.
CONCLUSIONS compared with 3 mg as initial dose, It is more rapid
and more effective to achieve therapeutic INR according to body mass
index (BMI) guiding the initial warfarin dosage, and bleeding event
did not add at the same time.GW26-e4473
Cholesterol in Remnant-Lipoproteins as Measured by Different Methods
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are associated with an increased risk of ischemic heart disease. The
concurrence of RLP-C measurement by different separation methods
is not well-described. This analysis assessed RLP-C by 3 commonly
used measurements including immunoseparation (IM [ApoA-I and
ApoB-100 monoclonal antibodies]), vertical auto proﬁle (VAP
[IDLþVLDL3]) and Calculated RLP-C (Total cholesterol minus HDL-C
minus LDL-C) methods using samples from a previously reported
randomized, clinical trial.
METHODS This analysis assessed fasting RLP-C in hyperlipidemic
patients (n¼2,382) treated with ezetimibe/simvastatin (E/S)10/20
mg, E/S þ niacin (N) 2g and N 2g during 24 weeks, and E/S 10/20
mg and E/S þ N 2g during 64 weeks. RLP-C levels, change from
baseline and % change from baseline were evaluated by the IM,
VAP, and Calculated methods. The relationships and agreement
among the 3 methods used in the measurement of these parameters
were assessed by Pearson correlation coefﬁcients and Bland-Altman,
respectively.
RESULTS Cholesterol mass at baseline measured by the VAP and
Calculated methods was w3-4X higher than by IM; all declined with
treatment by 24 weeks with little further reduction at 64 weeks (see
table). RLP-C change and % reduction from baseline were larger when
measured by VAP versus Calculated and IM methods. Although the 3
methods were moderately to strongly correlated (r¼0.37-0.79) for
RLP-C levels and changes, Bland-Altman plots showed little agree-
ment between the methods for RLP-C levels but slightly better
agreement for RLP-C changes (not shown).
CONCLUSIONS RLP-C deﬁned by IM, VAP and Calculated methods
differs in mass and response to pharmacologic intervention. Given the
relationship between RLP-C and IHD risk, standardization of methods
is needed for RLP-C use in risk assessment.GW26-e2366
Changes in Carotid Plaque Lipid Content in Subjects Who Continued and
Discontinued Statin Therapy
Ruixue Du, Ping Ye
The Department of Geriatric Cardiology & Department of Radiology,
Chinese PLA General Hospital, Beijing, China
OBJECTIVES Changes in carotid plaque lipid-rich necrotic core
(LRNC) as assessed by magnetic resonance imaging (MRI) were
investigated in subjects who continued and discontinued statin
therapy for 2 years after a prospective study.
METHODS The Rosuvastatin Evaluation of Atherosclerotic Chinese
Patients (REACH) study in 32 lipid treatment naïve subjects with
LRNC showed a signiﬁcant reduction in LRNC during 24 months (M) of
rosuvastatin therapy. All subjects received a clinical follow-up (F/U)
visit and a repeat carotid MRI scan at 48 M as planned REACH-F/U.
Despite receiving a strong recommendation to continue the statin
therapy at 24 M when REACH was completed, only 15 subjects
continued taking statins (rosuva.¼9, simva.¼4 and atorva.¼2) in
REACH-F/U and 17 discontinued. Lipids and LRNC, both in volume (V)
and % (LRNC-V/Wall V100%), were compared between the statin-
continued and -discontinued groups at 48 M.
RESULTS There were no signiﬁcant differences in demographic,
clinical characteristics, lipids and plaque changes during 24 M in
REACH between the statin-continued and -discontinued groups in
REACH-F/U. Not surprisingly, at 48 M, Total-Cholesterol (C), LDL-C
and triglycerides were signiﬁcantly lower in subjects who continued
statin than those discontinued (16343 vs. 20730 mg/dl, p¼0.002),
(9336 vs. 13122 mg/dl, p¼0.001) and (8527 vs. 14365 mg/dl,
p¼0.003), while HDL-C levels were similar. LRNC-V and %LRNC
decreased signiﬁcantly from 24 M in the statin-continued group
(10176 mm3 at 24 M vs. 7665 mm3 at 48 M, p¼0.001) and
(17.311.9% at 24 M vs. 12.67.6% at 48 M, p¼0.04). By contrast,
subjects who discontinued statin showed non-statistically signiﬁ-
cant increase in LRNC-V and %LRNC (10393 mm3 at 24 M vs.
112106 mm3 at 48 M, p¼0.4) and (15.411.3% at 24 Mvs.
16.711.4% at 48 M, p¼0.07). Furthermore, the changes in LRNC-V
and %LRNC from 24 to 48 M were signiﬁcantly different between
the statin-continued and -discontinued groups in REACH-F/U
(-2518 vs. 914 mm3, p<0.001) and (-4.6 8.2% vs. 1.32.8%,
p¼0.009).
CONCLUSIONS Continued statin therapy leads to continued decrease
in LRNC, which indicates improved plaque stability. The REACH-F/U
results provided vascular biological evidence to strongly support long-
term statin therapy.GW26-e3950
Uninterrupted Dabigatran versus Warfarin in the Treatment of Intracardiac
Thrombus in Patients with non-Valvular Atrial Fibrillation
Li Hao,1,2 Jingquan Zhong1
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Research, Chinese Ministry of Education and Chinese Ministry of
Health, Qilu Hospital; 2School of Medicine, Shandong University, Jinan,
China
OBJECTIVES The oral direct thrombin inhibitor dabigatran has a pre-
dictable anticoagulant effect and may be an alternative medication to
warfarin for non-valvular atrial ﬁbrillation (AF) patients with intracardiac
thrombus. The objective is to compare the dabigatran, administered at a
ﬁxed dose of 150 mg twice daily (bid) with dose-adjusted warfarin (with a
target international normalized ratio INR level of 2.0 to 3.0).
METHODS In the trial, 41 patients who had intracardiac thrombus
detected by transesophageal echocardiography (TEE) were enrolled.
Among them, 19 patients received dabigatran 150 mg bid and the
remaining 22 patients received warfarin based on the patients’ indi-
vidual choice. Repeated TEE was performed at 3 months. The patients
was assessed after 1 month and then 3 months in the clinic; meanwhile
they were requested to contact the investigator immediately if symp-
toms developed that were suggestive of stroke, thromboembolism or
major bleeding. All statistical analyses were conducted with SPSS Sta-
tistics version 17.0 software. The thrombus dissolution ability, repre-
sented by the ratio of decreased thrombus area to original area, was
compared by Wilcoxon W test between the 2 groups. Difference with p
value < 0.05 (2-sided) was considered statistically signiﬁcant.
RESULTS Mean age of the study population was 57.77.4 years, with
36 (87.8%) male and 17 (41.5%) patients who had persistent AF, with
no differences between the 2 groups. Thrombus area ranges from 0.1
to 4.48 cm2 and the locations of thrombi were mainly in left atrial
appendage (LAA). The thrombus area in warfarin group were larger
than in dabigatran group (1.451.04 vs. 0.640.54, p < 0.05). Mean
number of INR examination values obtained in the warfarin group was
10 during the therapy course. Time in therapeutic range of INR (TTR)
was above 60%. Complete thrombus resolution was documented by
repeated TEE in 17 patients in dabigatran group (17 of 19) and 17 pa-
tients in warfarin group (17 of 22). The ability of thrombus dissolution,
represented by the ratio of decreased thrombus area to original area,
was similar between the 2 groups (p > 0.05). Any bleeding, occurred in
7 patients receiving dabigatran and in 8 patients receiving warfarin.
No major or fatal bleeding occurred in both two groups. One patient in
the warfarin group experienced ischemic stroke. Four patients in the
dabigatran group had gastrointestinal discomfort. Only one patient
discontinued dabigatran for about two weeks and needed drug
intervention, and after 3-month anticoagulation, a secondary TEE
detected an increased thrombus.
CONCLUSIONS Dabigatran has similar effect compared with warfarin
for the treatment of intracardiac thrombus in patients with non-
valvular AF. Uninterrupted dabigatran is particularly essential and
crucial for ﬁbrinolysis and drug discontinuance would affect
thrombus dissolution effect. It should be noticed that dabigatran lead
to gastrointestinal discomfort event.
GW26-e0675
Comparison of Ticagrelor with Clopidogrel in the Treatment of Patients
with Acute Coronary Syndrome in Platelet Reactivity
Jingjing Li, Xiaowen Geng, Jie Gao, Yilun Chen, Yihong Ren
Department of Cardiovascular, General Hospital of PLA
OBJECTIVES To compare the inhibitory effect of ticagrelor and clo-
pidogrel on the platelet of patients with acute coronary syndro-
me(ACS) after percutaneous coronary artery intervention(PCI).
METHODS 255 cases of patients with ACS admitted in our hospital
from March 2014 to August 2014 were selected for this study, in which
85 cases were treated by ticagrelor and aspirin and the other 170 cases
were treated by clopidogrel and aspirin respectively. All the patients
were given PCI treatment, and the thrombelastography(TEG) were
detected 2 days after PCI and oral administration of load dosage of
antiplatelet drugs, the platelet inhibition ratio through ADP and AA
pathway were observed and compared between two groups.
RESULTS Adenosine diphosphate(ADP)-induced platelet inhibition
ratio in clopidogrel group was signiﬁcantly lower than that of in
ticagrelor group (66.6025.57% vs 82.1018.87%, P<0.05). Arach-
idonic acid(AA)-induced platelet inhibition ratio in clopidgrel was
similar to that of in ticagrelor group (88.7023.89% vs 90.3218.09%,
P>0.05). There were signiﬁcant differences between clopidogrel
